Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression
Tumor Biology · 2018-01 · 40 (1) · 101042831774825
DOI: 10.1177/1010428317748254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumor Biology, online erschienen am 10.01.2018. Verfasst von Mahmood Y Hachim und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1 Cancer Research Program, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
While TGFβ plays a critical role in tumor formation and progression, the role and contribution of its three different isoforms remain unclear. In this study, we aimed at elucidating the prognostic value of the TGFβ isoforms and assessed their expression levels in breast cancer patients at different stages of the disease. We found higher levels of TGFβ1 and TGFβ3 in cancer patients compared to normal tissues, with no significant changes in TGFβ2 expression. Similarly, TGFβ1 and TGFβ3, but not TGFβ2, showed higher expression levels in advanced lymph node–positive and metastatic tumors, suggesting different roles for the different isoforms in tumor progression and the metastatic process, while in the least aggressive molecular subtype (luminal A), expression of the three TGFβ isoforms significantly correlated with expression of both TGFβ receptors, such correlation only occurred between TGFβ1 and TGFβ3 and the TGFβ type II receptor (TβRII) in the highly aggressive basal-like subtype. Interestingly, a distinct and somehow opposite pattern was observed in HER-2 tumors, only showing significant association pattern between TGFβ2 and the TGFβ type I receptor (TβRI). Finally, the three TGFβ isoforms showed distinct association patterns with patient outcome depending on the different molecular subtype, highlighting context-dependent, differential prognostic values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1 Cancer Research Program, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
- 2 Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE.
Zitieren
APA
Hachim, M. Y., Hachim, I. Y., Dai, M., Ali, S., & Lebrun, J. J. (2018). Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression. Tumor Biology, 40(1), 101042831774825. https://doi.org/10.1177/1010428317748254
Vancouver
Hachim MY, Hachim IY, Dai M, Ali S, Lebrun JJ. Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression. Tumor Biology. 2018;40(1):101042831774825. doi:10.1177/1010428317748254
BibTeX
@article{Hachim2018,
author = {Hachim, Mahmood Y and Hachim, Ibrahim Y and Dai, Meiou and Ali, Suhad and Lebrun, Jean-Jacques},
title = {Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression},
journal = {Tumor Biology},
year = {2018},
volume = {40},
number = {1},
pages = {101042831774825},
doi = {10.1177/1010428317748254}
}
EUVIMED